News 
Market Data 
Discover
Writing
ragraham
Writing
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Writing
| Ticker | Board | News | Price | Change | Chg% | Added | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| GSK | GlaxoSmithKline | 41.775 | 0.165 | 0.40% | 12/14/2012 | |||||
|
My GSK Pitch: Glaxo's genital herpes vaccine flopped but next-gen herpes vaccines by Genocea, Agenus (AGEN), Vical (VICL) & Sanofi Pasteur (SNY) are buys in the genital herpes vaccine space. http://sandiegobiotechnology.com/topics/5600/glaxo-genital-herpes-vaccine-flops-but-genocea-a-buy-in-vaccine-space/
|
||||||||||
| ARNA | Arena Pharmaceuticals, Inc. | 11/27/2012 | ||||||||
|
My ARNA Pitch: Two important policy shifts at the federal level bode well for much broader coverage of weight loss treatment, counseling and prescription weight-loss medicines, including Arena Pharmaceuticals' Belviq and Vivus, Inc.'s Qsymia. http://bit.ly/QJMUWw
|
||||||||||
| SGMO | Sangamo Biosciences Inc | 0.5077 | -0.0146 | -2.80% | 11/16/2012 | |||||
|
My SGMO Pitch: Sangamo BioSciences (SGMO)has "functional cured" HIV patients in a clinical trials. Sangamo has protected IP in zinc finger nuclease technology and is protecting IP in a similar gene-editing tech called TALENs. Either platform could be used to "cure" HIV and other diseases. http://bit.ly/WayJ
|
||||||||||
| ILMN | Illumina Inc | 124.65 | -0.08 | -0.06% | 10/22/2012 | |||||
|
My ILMN Pitch: Infertile women will soon get the biggest baby boost in a generation from preimplantation genetic diagnosis. To capitalize on this emerging market, Illumina (ILMN) in September acquired BlueGnome. http://bit.ly/PMJXUf
|
||||||||||
| CRXM | Taxus Cardium Pharmaceuticals Group Inc | 0.000001 | 0.0 | 0.00% | 10/02/2012 | |||||
|
My CRXM Pitch: It’s more than 5-hour energy jolt. Cardium Therapeutics’ purchase of To Go Brands and its sales network will help Cardium get more of the $30 billion supplements market:
https://sandiegobiotechnology.com/topics/5393/cardium-boosts-energy-supplement-sales-with-national-marketing-muscle/ |
||||||||||
| MON | Monument Circle Acquisition Corporation | 0 | 0 | 0.00% | 09/18/2012 | |||||
|
My MON Pitch: Anecdotal reports from farmers indicate Monsanto’s drought-tolerant corn did well in field tests in U.S. Midwest. Yield was 6 more bushels/acre than competitor hybrids. Seed sales of Monsanto’s DroughtGard, the only GM corn approved for U.S., should be very good in 2013. http://bit.ly/QXOSiM
|
||||||||||
| Vivus Inc fka VVUSQ | 07/26/2012 | |||||||||
|
My Pitch: Neuropharmacology said diet pill Qsymia, by Vivus (VVUS), leads to a wt. loss of 9.4%: Orexigen’s (OREX) Contrave had 5.2 % loss; and Arena’s (ARNA) Belviq had only 3-3.7%. http://sandiegobiotechnology.com/topics/4765/fda-approves-top-rated-new-diet-pill-vivus-inc-s-qsymia/
|
||||||||||
| VRNM | Verenium Corporation | 07/26/2012 | ||||||||
| Sequenom Corp fka SQNM | 07/26/2012 | |||||||||
